Aqilion publishes the Annual Report for 2021
AQILION AB (publ) hereby announces that the Swedish version of the 2021 Annual Report has been published.
The Annual Report, which is attached in Swedish, can also be downloaded from the company’s website. An English translation of the Annual Report is estimated to become available on the website no later than in the week commencing June 13, 2022.
For more information, please contact:
Sarah Fredriksson, CEO, AQILION AB, + 46 (0)70 261 4575, email@example.com
Aqilion is a biotech company that focuses on developing new innovative treatments for diseases caused by chronic inflammation and dysfunctional immune reactions such as autoimmune diseases. The company is mainly active in the early phases of drug discovery, from idea to early clinical development.
Aqilion combines its experience from major pharmaceutical companies with the drive and entrepreneurship of small growth companies. With solid experience of business development in innovative biotech and pharmaceutical companies, Aqilion’s experienced team and board have successfully shepherded drugs all the way from discovery to market.
AQILION AB (publ) is a Swedish public limited company headquartered in Helsingborg, Sweden. www.aqilion.com